Effect of sitagliptin combined with metformin on type 2 diabetes mellitus and its influences on blood glucose variability,SAA and α2-MG levels
Objective To analyze the effect of sitagliptin combined with metformin in the treatment of type 2 diabetes mellitus(T2DM)and its influences on blood glucose variability,serum amyloid A(SAA)and α2-macroglobulin(α2-MG)levels.Methods A total of 110 patients with T2DM admitted in our hospital from January 2020 to March 2022 were selected as the research objects and divided into control group(n=55)and observation group(n=55)by random number table method.The control group was treated with glimepiride combined with metformin,and the observation group was treated with sitagliptin combined with metformin.The therapeutic effects of the two groups were compared.Results After treatment,the mean of daily differences(MODD),standard deviation(SD),last amplitude of glycaemic excursion(LAGE)and mean amplitude of glycemic excursions(MAGE)in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the coefficient of variation of blood glucose(CV)and coefficient of variation of fasting blood glucose(CV-FBG)in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of SAA and α2-MG in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Sitagliptin and glimepiride combined with metformin in the treatment of T2DM can effectively control blood glucose,but sitagliptin combined with metformin has better control effect on blood glucose variability and blood glucose fluctuation,and can also regulate SAA and α2-MG levels,which is worthy of promotion.
NETL
NSTL
万方数据
